Istavel Empa 10 Tablet is a combination oral antidiabetic medication containing Empagliflozin 10 mg and Sitagliptin 100 mg, indicated for the management of type 2 diabetes mellitus. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. The synergistic action of these agents improves glycemic control by targeting complementary pathophysiological mechanisms. Istavel Empa 10 is prescribed as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or other antidiabetic regimens. Clinical studies have demonstrated its efficacy in reducing HbA1c levels, fasting plasma glucose, and postprandial glucose excursions. The combination is generally well-tolerated; however, patients should be monitored for potential adverse effects such as urinary tract infections, genital mycotic infections, hypoglycemia (especially when used with insulin or sulfonylureas), and volume depletion. Renal function should be assessed prior to initiation and periodically thereafter. Istavel Empa 10 offers a convenient once-daily dosing option, contributing to improved patient adherence in type 2 diabetes management.